GA NCORP

NCORP Trials

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT03651128
Protocol IDs
BB2121-MM-003 (primary)
2018-001023-38
NCI-2018-02057
U1111-1217-9988
Study Sponsor
Celgene

Summary

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and
safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple
myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254
subjects will be randomized to Treatment Arm A and approximately 127 subjects will be
randomized to Treatment Arm B.

Treatment Sites


Atlanta Cancer Care - Conyers
1498 Klondike Road
Suite 106
Conyers, GA 30094
404-303-3355
www.atlantacancercare.com

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
Northside Hospital Central Research Department
404-303-3355
www.northside.com

Study Coordinator:
Stacey Brown
404-780-7965

Doctors:

Asad Bashey MD, PhD
H. Kent Holland MD
Lawrence E. Morris, Jr. MD
Scott R. Solomon MD
Melhem Solh MD